Roth Capital increased its price target on AcelRx because it raised its price estimate per dose of the company's Zalviso drug to 420 from $15 and now sees a 75% chance of it being approved, up from 50% previously. The firm believes that ,following a meeting with the FDA, the company intends to launch "a small trial or two" at the beginning of 2016, in order to assuage doubts that the agency has vis-a-vis the drug. However, the firm continues to believe that Zalviso will be approved without repeating the three previous Phase 3 trials. Roth keeps a Buy rating on the stock.